Zilver PTX Three-Year Trial Data Show Higher Freedom From Target Lesion Revascularization Rates
August 15, 2012 — Previously unreleased three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease indicate that Cook Medical’s paclitaxel-eluting peripheral vascular stent demonstrated 83 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479-patient study.
Gary M. Ansel, M.D., principal investigator of the Zilver PTX study, presented the study findings at the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) meeting last month in Niigata, Japan.
The device is currently available for sale in Japan after approval from the Pharmaceuticals and Medical Devices Agency on Jan. 24 and is now available in more than 45 countries. It is currently under U.S. Food and Drug Administration (FDA) review and is not available for sale in the United States. Ansel is a paid consultant to Cook Medical with respect to its medical devices.
For more information: www.cookmedical.com
More like this
- Cook’s Zilver PTX Trial Shows Sustained Patency After Three Years
- At Nine Months, SFA Stent Trial Shows Promise for PAD Patients
- Trial Establishes Benefit of Drug-Eluting Stent in PAD
- European Trial Explores Potential of Renal Stent
- Cook Medical Receives Japanese Approval for Zilver PTX Drug-Eluting Stent